МОЛЕКУЛЯРНО-ГЕНЕТИЧЕСКИЕ ОСОБЕННОСТИ КЛИНИЧЕСКОГО ПРОГНОЗА ГЦР
Аннотация
Ключевые слова
Об авторах
Н. Л. Лазаревич
Научно-исследовательский институт канцерогенеза Российского онкологического научного центра имени Н.Н. Блохина; Московский государственный университет имени М.В.Ломоносова
Россия
Россия
Лазаревич Наталия Леонидовна — НИИ Канцерогенеза РОНЦ им. Н. Н. Блохина, биологический факультет МГУ им. М. В. Ломоносова, Москва
О. М. Кривцова
Научно-исследовательский институт канцерогенеза Российского онкологического научного центра имени Н.Н. Блохина; Московский государственный университет имени М.В.Ломоносова
Россия
Россия
Кривцова Ольга Михайловна — НИИ Канцерогенеза РОНЦ им. Н. Н. Блохина, биологический факультет МГУ им. М. В. Ломоносова, Москва
П. А. Сковородникова
Научно-исследовательский институт канцерогенеза Российского онкологического научного центра имени Н.Н. Блохина; Московский государственный университет имени М.В.Ломоносова
Россия
Россия
Сковородникова Полина Андреевна — НИИ Канцерогенеза РОНЦ им. Н. Н. Блохина, биологический факультет МГУ им. М. В. Ломоносова, Москва
Список литературы
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2): 87–108.
2. Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): An emerging field for advanced technologies. J Hepatol. 2012; 56(1): 267–275.
3. Calvisi DF, Frau M, Tomasi ML, Feo F, Pascale RM. Deregulation of signalling pathways in prognostic subtypes of hepatocellular carcinoma: Novel insights from interspecies comparison. Biochim Biophys Acta — Rev Cancer. 2012; 1826(1): 215–237.
4. Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. J Hepatol. 2016. pii: S0168–8278(16)30249–5.
5. Han ZG. Functional Genomic Studies: Insights into the Pathogenesis of Liver Cancer. Annu Rev Genomics Hum Genet. 2012; 13(1): 171–205.
6. Lee JS, Chu IS, Heo J., Calvisi DF, Sun Z, Roskams T, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004; 40: 667–676.
7. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009; 69: 7385–7392.
8. Boyault S, Rickman DS, De Reyni s A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007; 45: 42–52.
9. Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology. 2011; 140(5): 1501–12.e2.
10. Nault JC, De Reynies A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology. 2013; 145: 176–187.
11. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008; 359: 1995–2004.
12. Ji J, Yu L, Yu Z, Forgues M, Uenishi T, Kubo S, et al. Development of a miR-26 companion diagnostic test for adjuvant interferon-alpha therapy in hepatocellular carcinoma. Int J Biol Sci. 2013; 9(3): 303–12.
13. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene. 2010; 29(16): 2309–2324.
14. Röcken C, Carl-McGrath S. Pathology and Pathogenesis of Hepatocellular Carcinoma. Dig Dis. 2001; 19(4): 269–278.
15. Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: A cancer hallmarks analysis. Cell Host Microbe. 2014; 15(3): 266–282.
16. Marquardt JU, Seo D, Andersen JB, Gillen MC, Kim MS, Conner EA, et al. Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. J Hepatol. 2014; 60(2): 346–53.
17. Nakashima O, Kojiro M. Recurrence of hepatocellular carcinoma: multicentric occurrence or intrahepatic metastasis? A viewpoint in terms of pathology. J Hepatobiliary Pancreat Surg. 2001; 8(5): 404–409.
18. Miao R, Luo H, Zhou H, Li G, Bu D, Yang X, et al. Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. J Hepatol. 2014; 61(4): 840–849.
19. Консервативное лечение первичного и метастатического рака печени / Под ред. В. А. Горбуновой. — 288 c., М.: ООО «Медицинское информационное агентство», 2013.
20. Xue R, Li R, Guo H, Guo L, Su Z, Ni X, et al. Variable Extent of Intra-tumor Heterogeneity Revealed by Genomic Sequencing of Multiple Lesions in Patients with Hepatocellular Carcinoma. Gastroenterology. 2016; 150(4): 998–1008.
21. Wang B, Xia CY, Lau WY, Lu XY, Dong H, Yu WL, et al. Determination of clonal origin of recurrent hepatocellular carcinoma for personalized therapy and outcomes evaluation: a new strategy for hepatic surgery. J Am Coll Surg. 2013; 217(6): 1054–1062.
22. Matsumoto Y, Fujii H, Matsuda M, Kono H. Multicentric occurrence of hepatocellular carcinoma: diagnosis and clinical significance. J Hepatobiliary Pancreat Surg. 2001; 8(5): 435–440.
23. Li Q, Wang J, Juzi JT, Sun Y, Zheng H, Cui Y, et al. Clonality analysis for multicentric origin and intrahepatic metastasis in recurrent and primary hepatocellular carcinoma. J Gastrointest Surg. 2008; 12(9): 1540–1547.
24. Lu LC, Hsu CH, Hsu C, Cheng AL. Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges. Liver Cancer. 2016; 5(2): 128–138.
25. Arii S, Teramoto K, Kawamura T, Okamoto H, Kaido T, Mori A, Imamura M. Characteristics of recurrent hepatocellular carcinoma in Japan and our surgical experience. J Hepatobiliary Pancreat Surg. 2001; 8(5): 397–403.
26. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 1992; 258(5083): 818–821.
27. Vogelstein B, Fearon ER, Feinberg AP. Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors. Science. 1985; 227(4687): 642–645.
28. Welsh J, McClelland M. Fingerprinting genomes using PCR with arbitrary primers. Nucleic acids research. 1990; 18(24): 7213–7218.
29. Shi JY, Xing Q, Duan M, Wang ZC, Yang LX, Zhao YJ, et al. Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity. Oncotarget. 2016; 7(3): 2867.
30. Liu S, Chan KW, Wang B, Qiao L. Fibrolamellar hepatocellular carcinoma. Am. J. Gastroenterol. 2009; 104: 2617–2624.
31. Honeyman JN, Simon EP, Robine N, Chiaroni-Clarke R, Darcy DG, Lim II, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. 2014; 343(6174): 1010–1014.
32. Xu L, Hazard FK, Zmoos AF, Jahchan N, Chaib H, Garfin PM, et al. Genomic analysis of fibrolamellar hepatocellular carcinoma. Hum Mol Genet. 2015; 24(1): 50–63.
33. Cornella H, Alisnet C, Sayols S, Zhang Z, Hao K, Cabellos L, et al. Unique genomic profile of fibrolamellar hepatocellular carcinoma. Gastroenterology. 2015; S0016–5085(14)01580–7.
34. Chan SL, Wong AM, Lee K, Wong N, Chan AK. Personalized therapy for hepatocellular carcinoma: Where are we now? Cancer Treat Rev. 2016; 45: 77–86.
35. Heindryckx F, Gerwins P. Targeting the tumor stroma in hepatocellular carcinoma. World J Hepatol. 2015; 7(2): 165–176.
36. Lavi O, Skinner J, Gottesman MM. Network features suggest new hepatocellular carcinoma treatment strategies. BMC Syst Biol. 2014; 8: 88.
Рецензия
Для цитирования:
Лазаревич Н.Л., Кривцова О.М., Сковородникова П.А. МОЛЕКУЛЯРНО-ГЕНЕТИЧЕСКИЕ ОСОБЕННОСТИ КЛИНИЧЕСКОГО ПРОГНОЗА ГЦР. Злокачественные опухоли. 2016;(4s1):40-45.
Просмотров: 620
Послать статью по эл. почте 